Navigation Links
Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
Date:6/27/2011

43 necessary to complete an Investigational New Drug application, which it plans to submit to the U.S. Food and Drug Administration next month.

"These studies add to our growing collection of data regarding the activity of our compounds and their potential ability to enhance the effects of current treatments," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "These data further support the clinical development strategy for our lead candidate NV-143, the primary metabolite of Triphendiol, in combination with standard-of-care chemotherapy, while expanding the potential drug combinations we can consider in our randomized Phase II clinical trials."

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes Triphendiol and lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statem
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
2. Marshall Edwards Announces Private Placement
3. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards to Host Annual Meeting of Stockholders
6. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
7. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
8. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
9. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Uroplasty, Inc. (Nasdaq: UPI ) announced ... second quarter ended September 30, 2010, at the market ... host a conference call to discuss these results on ...  David Kaysen, President and Chief Executive Officer, and Medi ...
... Corporation (OTCQB: CGCP) announced that the company will release ... on Wednesday, November 3, 2010.  The company added that ... Abbott, its Senior Vice President and Chief Financial Officer, ... 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to ...
Cached Medicine Technology:Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010 2Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd 2
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... to some countries where data doesn,t match WHO ... About 7 million fewer children are immunized against ... nations and World Health Organization/UNICEF estimates report, a ... funding for vaccinations based on these estimates, the ...
... LifeBanc, the nonprofit,organ and tissue recovery organization for Northeast ... conference announcing the first,near total face transplant in the ... The following statement is from LifeBanc Chief Executive Officer ... keeping with LifeBanc,s mission of helping to improve and ...
... JEFFERSON CITY, Mo., Dec. 17 The Missouri ... the Substance Abuse and,Mental Health Services Administration (SAMHSA) ... Service Awards. These awards "recognize,exemplary implementation of ... treat mental illnesses and substance abuse"(1). , ...
... spiritual experiences are based in the brain. That statement ... of Missouri neuropsychologist. An MU study has data to ... with selflessness are related to decreased activity in the ... one of the first to use individuals with traumatic ...
... people an advantage in battling cancer, a University of ... Lancet Oncology , provides evidence that varying body compositions ... rates, activity levels during the illness and potentially, even ... of 250 obese cancer patients were viewed in the ...
... for itchy skin condition , , WEDNESDAY, Dec. 17 (HealthDay News) ... to the development of eczema may one day lead to ... -- at least if new research with mice applies to ... of mice -- one that had a receptor for the ...
Cached Medicine News:Health News:Independent Audit of Global Child Immunizations Urged 2Health News:LifeBanc Assists Cleveland Clinic in First Near Total Face Transplant in the United States 2Health News:Missouri Behavioral Pharmacy Management Program Receives 2008 SAMHSA Science and Service Award 2Health News:Missouri Behavioral Pharmacy Management Program Receives 2008 SAMHSA Science and Service Award 3Health News:Selflessness, core of all major world religions, has neuropsychological connection 2Health News:Manipulating Key Protein May Prevent Eczema 2
For the determination of urea nitrogen in human serum....
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... The 1100 Spectrophotometers ... economical. Great for use ... laboratories, including educational, clinical, ... Options include COD vial ...
Medicine Products: